Holen Sie sich die Stockscreener-App
0.00
100.00%
-28.69
Schlusskurs vom Vortag:
$28.69
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$1.73B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-15.84M
KGV:
0.00
EPS:
-12.1
Netto-Cashflow:
$-12.23M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$38.33
Damora Therapeutics Inc Stock (GLTO) Company Profile
Firmenname
Damora Therapeutics Inc
Sektor
Branche
Telefon
45-70-70-52-10
Adresse
75 STATE STREET, BOSTON
Compare GLTO vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GLTO
Damora Therapeutics Inc
|
0.00 | 1.73B | 0 | -15.84M | -12.23M | -12.10 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Damora Therapeutics Inc Stock (GLTO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-24 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-03-25 | Eingeleitet | Evercore ISI | Outperform |
| 2026-02-17 | Eingeleitet | UBS | Buy |
| 2026-01-07 | Eingeleitet | Leerink Partners | Outperform |
| 2025-12-01 | Eingeleitet | Guggenheim | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-11-23 | Eingeleitet | BofA Securities | Buy |
| 2020-11-23 | Eingeleitet | Credit Suisse | Outperform |
| 2020-11-23 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Damora Therapeutics Inc Aktie (GLTO) Neueste Nachrichten
Damora Therapeutics, Inc. Common Stock (DMRA) Stock Trends and Sentiment 2026 - MarketBeat
DMRA Technical Analysis & Stock Price Forecast - Intellectia AI
Damora Therapeutics, Inc. Common Stock (DMRA) Institutional Ownership 2026 - MarketBeat
Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026 - MarketBeat
Will Widening Net Losses And New Finance Chief Change Damora Therapeutics' (DMRA) Narrative - Sahm
Damora Therapeutics, Inc. Common Stock (DMRA) Stock Chart and Price History 2026 - MarketBeat
Damora Therapeutics, Inc. Common Stock (DMRA) Stock Forecast and Price Target 2026 - MarketBeat
Point72-backed entities report 1.19M shares in Damora (DMRA) - Stock Titan
Damora Therapeutics (DMRA) filing: Jain Global group reports 0.0% stake - Stock Titan
Avoro Capital (DMRA) and Dr. Aghazadeh report 3.78M shares (6.27%) - Stock Titan
Damora Therapeutics, Inc. Common Stock (DMRA) Financials 2026Income Statement and Balance Sheet - MarketBeat
Damora Therapeutics, Inc. Stock 12‑Month Price Target Cut to $44.5, Implies 93% Upside - TradingView
Damora's $533M Gambit: New Leadership Targets Rare Blood Cancers - BriefGlance
RBC Capital Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $40 - Moomoo
DMRA SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights - The Manila Times
Damora Therapeutics 1Q 2026: Net loss $27.8M — 10-Q Summary - TradingView
Damora funds 3 blood-disorder drugs with $533M cash into 2029 - Stock Titan
Damora Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Damora Therapeutics (DMRA) ramps mutCALR R&D with major cash raise - Stock Titan
Damora Therapeutics, Inc. Common Stock (DMRA) Short Interest & Short Float | Updated May 2026 - MarketBeat
Damora Therapeutics, Inc. Common Stock (DMRA) Earnings Date and Reports 2026 - MarketBeat
Number of shareholders of Damora Therapeutics, Inc. – NASDAQ:DMRA - TradingView
What Damora Therapeutics (DMRA)'s CEO Shake-Up and Finance Refresh Means For Shareholders - Yahoo Finance
Damora Therapeutics (DMRA) SVP reports 312,535-share stock option grant - Stock Titan
A Look At Damora Therapeutics (DMRA) Valuation After Recent Share Price Momentum And Negative Equity Signals - Sahm
Damora Therapeutics Appoints Jennifer Jarrett as New Chief Executive - HarianBasis.co
Damora Therapeutics (DMRA) Appoints Jennifer Jarrett as President, Chief Executive Officer - Yahoo Finance
Assessing Damora Therapeutics (DMRA) Valuation After CFO Transition And Recent Share Price Momentum - Yahoo Finance
Damora Therapeutics Announces CFO Transition to Internal Leader - TipRanks
5 Best Performing NASDAQ Stocks According to Wall Street Analysts - Insider Monkey
Damora Therapeutics: Lori Firmani to cease serving as CFO effective May 1, 2026SEC filing - marketscreener.com
Damora Therapeutics (NASDAQ: DMRA) replaces CFO, elevating SVP finance - Stock Titan
Finanzdaten der Damora Therapeutics Inc-Aktie (GLTO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Damora Therapeutics Inc-Aktie (GLTO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | Director |
Feb 09 '26 |
Option Exercise |
0.00 |
8,713,000 |
0 |
5,809,000 |
| Schambye Hans T. | Chief Executive Officer |
Jan 02 '26 |
Sale |
21.38 |
700 |
14,966 |
4,682 |
| Winslow Garrett | General Counsel |
Jan 02 '26 |
Sale |
21.38 |
255 |
5,452 |
1,854 |
| Firmani Lori | Chief Financial Officer |
Jan 02 '26 |
Sale |
21.41 |
135 |
2,890 |
931 |
| Schambye Hans T. | Chief Executive Officer |
Jul 03 '25 |
Sale |
3.38 |
735 |
2,484 |
4,022 |
| Winslow Garrett | General Counsel |
Jul 03 '25 |
Sale |
3.39 |
260 |
881 |
1,429 |
| Firmani Lori | Interim CFO |
Jul 03 '25 |
Sale |
3.39 |
147 |
498 |
692 |
2.98%
1.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):